Track Glenmark Pharmaceuticals live share price with 52 week high and low, interactive chart views, quick fundamentals, financial statements, business segments, ratios, peer comparison, dividends, bonuses/splits and clear investor FAQs.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views. The chart uses the Yahoo Finance-compatible NSE symbol GLENMARK.NS.
These snapshot numbers help beginners understand valuation, price range, trading volume and per-share fundamentals. Live feed values may differ from official filings because market data updates continuously.
Data note: verify the latest market cap, P/E, book value, EPS, dividend yield and 52 week range from NSE, BSE, the company’s investor relations page and your broker before using them for investment decisions.
Glenmark Pharmaceuticals Ltd is a research-led global pharmaceutical company with operations across branded, generic and innovation-led pharmaceutical markets. The company is associated with therapies such as respiratory, dermatology and oncology and has a presence across India, North America, Europe and other international markets.
For customers, Glenmark is relevant because it supplies prescription and other healthcare products through regulated channels. For investors, the company is usually studied as a mid-cap Indian pharmaceutical stock whose performance can be influenced by new launches, approvals, pricing, manufacturing compliance, litigation, R&D progress and currency movements.
This page is educational. It explains the company’s share price context, business model and financial trends without giving a buy, sell or hold recommendation.
Investors generally monitor Glenmark through India formulations, North America generics, Europe, rest-of-world markets and research-led or specialty opportunities. Important questions include whether revenue is growing sustainably, whether margins are improving, whether debt and working capital are under control and whether regulatory updates remain manageable.
Glenmark makes money by researching, developing, manufacturing, marketing and distributing pharmaceutical products. In branded markets, growth depends on doctor prescriptions, product quality, brand recall and field execution. In generic markets, growth depends on regulatory approvals, supply reliability, launch timing, price competition and manufacturing compliance.
Pharmaceutical companies can have uneven profits because a single year may include exceptional items, litigation costs, plant remediation costs, product launch benefits or currency gains/losses. Beginners should read both the reported numbers and the management notes to understand the quality of earnings.
| Segment / Area | What it covers | What customers and investors monitor |
|---|---|---|
| India branded formulations | Prescription brands across important therapies such as respiratory, dermatology, cardiac, anti-infective and other chronic or acute categories. | Doctor prescriptions, brand strength, market-share movement, new launches and pricing policy. |
| North America generics | Finished dosage formulations and selected generic products for the US and related markets. | USFDA compliance, product approvals, pricing pressure, competition and launch timing. |
| Europe | Generic and branded generic products sold across European markets. | Market expansion, margin quality, regulatory approvals and currency movement. |
| RoW and emerging markets | Sales across Asia, Middle East, Africa, Latin America, Russia/CIS and other international regions. | Country mix, tender business, distributor performance and currency volatility. |
| Innovation and specialty pipeline | Research-led opportunities, including Glenmark’s innovation platform and selected oncology-focused assets. | Clinical milestones, partner updates, R&D spending and probability of commercialization. |
The following table gives a beginner-friendly view of recent segment-level highlights. These figures are rounded and should be checked against the latest company presentations, annual reports and exchange filings.
| Area | Latest reported highlight | Beginner explanation |
|---|---|---|
| India business | FY2025 growth of 31.9% to about ₹4,484.5 Cr | Shows domestic formulation momentum; verify latest annual and quarterly filings for updated sales mix. |
| Europe business | FY2025 growth of 17.6% to about ₹2,846.3 Cr | A useful indicator of international execution outside India and North America. |
| RoW business | FY2025 growth of 1.7% to about ₹2,813.8 Cr | Tracks emerging market contribution where currency and country-specific demand can affect growth. |
| North America | Q4 FY2025 revenue of about ₹714.6 Cr, down 5.4% YoY | North America can be volatile because generic pricing, approvals and compliance updates matter. |
| Q4 FY2025 adjusted PAT | About ₹346.6 Cr with adjusted PAT margin of 10.6% | Adjusted profit excludes specified exceptional items; compare with reported profit and notes. |
Verification note: business segment numbers can be restated, reclassified or updated after new quarterly or annual results. Always verify the latest segment revenue and margin details from official company and exchange filings.
The profit and loss statement shows sales, expenses, operating profit, margins and net profit. For Glenmark, investors should pay attention to one-time items, legal costs, manufacturing remediation costs and product launch benefits because these can affect year-to-year comparability.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | ₹11,813 Cr | ₹13,322 Cr | ₹16,983 Cr |
| Expenses | ₹10,618 Cr | ₹10,970 Cr | ₹12,410 Cr |
| Operating Profit | ₹1,195 Cr | ₹2,351 Cr | ₹4,572 Cr |
| OPM | 10% | 18% | 27% |
| Other Income | ₹336 Cr | -₹259 Cr | -₹1,805 Cr |
| Interest | ₹516 Cr | ₹207 Cr | ₹209 Cr |
| Depreciation | ₹582 Cr | ₹486 Cr | ₹573 Cr |
| Profit Before Tax | ₹434 Cr | ₹1,399 Cr | ₹1,985 Cr |
| Net Profit | -₹1,434 Cr | ₹1,047 Cr | ₹1,362 Cr |
| EPS | -₹53.22 | ₹37.11 | ₹48.26 |
| Dividend Payout | -5% | 7% | 5% |
Financial note: these rounded financial highlights are for education. Verify the latest audited and unaudited profit and loss numbers, exceptional items and EPS from official exchange filings and annual reports.
The balance sheet shows what the company owns and owes. For a pharmaceutical company, investors often monitor borrowings, reserves, fixed assets, working capital, investments and whether cash generation is improving.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | ₹28 Cr | ₹28 Cr | ₹28 Cr |
| Reserves | ₹7,820 Cr | ₹8,821 Cr | ₹10,484 Cr |
| Borrowings | ₹1,231 Cr | ₹2,473 Cr | ₹594 Cr |
| Other Liabilities | ₹5,279 Cr | ₹4,669 Cr | ₹8,802 Cr |
| Total Liabilities | ₹14,358 Cr | ₹15,991 Cr | ₹19,908 Cr |
| Fixed Assets | ₹4,210 Cr | ₹4,487 Cr | ₹6,396 Cr |
| Capital Work in Progress | ₹662 Cr | ₹835 Cr | ₹428 Cr |
| Investments | ₹790 Cr | ₹56 Cr | ₹42 Cr |
| Other Assets | ₹8,697 Cr | ₹10,613 Cr | ₹13,042 Cr |
| Total Assets | ₹14,358 Cr | ₹15,991 Cr | ₹19,908 Cr |
Balance sheet note: verify the latest debt, reserves, assets, liabilities and capital work in progress from audited accounts and exchange filings before drawing conclusions.
Cash flow helps investors check whether accounting profit is turning into cash. A pharma company may have working-capital swings because of receivables, inventories, regulatory timelines, launches and international sales cycles.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from Operating Activity | -₹265 Cr | -₹828 Cr | ₹3,445 Cr |
| Cash from Investing Activity | ₹4,387 Cr | ₹58 Cr | -₹1,283 Cr |
| Cash from Financing Activity | -₹3,906 Cr | ₹787 Cr | -₹2,709 Cr |
| Net Cash Flow | ₹215 Cr | ₹17 Cr | -₹547 Cr |
| Free Cash Flow | -₹1,162 Cr | -₹1,575 Cr | ₹2,090 Cr |
| CFO / Operating Profit | 65% | -6% | 92% |
Cash flow note: cash flow can move sharply because of working capital, asset sales, repayments, capex or one-time items. Verify the latest cash flow statement from official filings.
Ratios simplify financial statements. For Glenmark, useful ratios include ROCE, working-capital days, debtor days, inventory days, cash conversion cycle, sales growth, profit growth and return on equity.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 / Latest |
|---|---|---|---|
| ROCE | 12% | 19% | 40% |
| Debtor Days | 57 | 92 | 107 |
| Inventory Days | 208 | 254 | 264 |
| Days Payable | 210 | 216 | 288 |
| Cash Conversion Cycle | 56 days | 129 days | 83 days |
| Working Capital Days | -2 days | 44 days | 81 days |
| Compounded Sales Growth | 10Y: 8% | 5Y: 9% | 3Y: 14%; TTM: 27% |
| Compounded Profit Growth | 10Y: 15% | 5Y: 26% | 3Y: 76%; TTM: 124% |
| Return on Equity | 10Y: 8% | 5Y: 3% | Last year: 30% |
Ratio note: ratios depend on the source, period, consolidation method and exceptional adjustments. Verify the latest ratios from official filings or recalculate them from audited statements.
Peer comparison helps users avoid studying one company in isolation. Glenmark can be compared with other Indian pharmaceutical companies, but each peer has a different therapy mix, geography, R&D pipeline, regulatory history and valuation profile.
| Company | Symbol | Market Cap | Price | P/E | 52W High / Low | Dividend Yield |
|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | GLENMARK.NS | — | — | — | — | — |
| Sun Pharmaceutical Industries Ltd | SUNPHARMA.NS | — | — | — | — | — |
| Cipla Ltd | CIPLA.NS | — | — | — | — | — |
| Dr. Reddy’s Laboratories Ltd | DRREDDY.NS | — | — | — | — | — |
| Lupin Ltd | LUPIN.NS | — | — | — | — | — |
| Torrent Pharmaceuticals Ltd | TORNTPHARM.NS | — | — | — | — | — |
| Alkem Laboratories Ltd | ALKEM.NS | — | — | — | — | — |
Peer note: peer market data is refreshed from the latest available feed when possible. Verify current prices, valuation multiples and peer set from exchange data and company filings.
Corporate actions affect shareholder records and historical price charts. Dividends distribute cash, bonuses increase share count, and splits change face value and number of shares without changing the underlying business value by themselves.
| Year / Item | Dividend Detail | Note |
|---|---|---|
| Latest dividend | Verify from board recommendation, annual report and NSE/BSE filings | Dividend amount, ex-date, record date and payment date can change only through official announcements. |
| FY 2024-25 indicator | Dividend payout shown at about 7% in the financial summary | Use the audited annual report and exchange filings for final dividend history. |
| FY 2025-26 indicator | Dividend payout shown at about 5% in the financial summary | Check whether the latest year is audited, unaudited or updated after board approval. |
| Dividend yield | Shown in quick fundamentals when available from the market feed | Dividend yield changes whenever the share price or dividend amount changes. |
| Action | Detail | Note |
|---|---|---|
| Face Value | ₹1.00 | Verify latest face value from NSE, BSE and company filings before using it. |
| Bonus Issue | No bonus ratio is hard-coded on this page | Check official corporate action announcements for any bonus issue and record date. |
| Stock Split | No split ratio is hard-coded on this page | Check official corporate action announcements for any split ratio and effective date. |
Corporate action note: always verify the latest dividend, bonus, split, face value, ex-date and record date details from official NSE/BSE filings and company announcements before acting on them.
These FAQs answer common AI-search-style questions about Glenmark Pharmaceuticals, its products, business model, risks, dividends, share price data and investment monitorables. They are educational and do not replace medical advice or investment advice.
Glenmark Pharmaceuticals is an Indian research-led global pharmaceutical company. It sells branded medicines, generic medicines and selected OTC or consumer healthcare products across India, North America, Europe and emerging markets. Its important therapeutic focus areas include dermatology, respiratory and oncology. Medicine users should rely on doctors, pharmacists and official product labels for medical decisions.
The NSE symbol is GLENMARK and the Yahoo Finance-compatible symbol used on this page is GLENMARK.NS. The BSE code is 532296. Investors should verify symbols and corporate action details from NSE, BSE and company filings before placing any trade.
The company earns revenue by developing, manufacturing, marketing and distributing pharmaceutical products. Its business depends on prescription demand, product launches, pricing, regulatory approvals, manufacturing quality, geographic mix and competition in branded and generic markets.
Retail investors commonly track India branded formulations, North America generics, Europe, rest-of-world/emerging markets and the innovation pipeline. Each segment has different drivers, such as doctor prescriptions, product approvals, pricing pressure, currency movement and regulatory compliance.
No. Glenmark has a mix of branded, generic and innovation-led pharmaceutical operations. Generic products remain important, but the company also focuses on branded portfolios and selected research or specialty opportunities. The exact revenue mix should be checked from the latest annual report or investor presentation.
Customers should use any prescription medicine only under medical supervision and should read the approved label, dosage instructions, warnings and storage instructions. This stock page is for company and market education only and is not medical advice.
Key risks include regulatory observations at manufacturing sites, US generics price pressure, litigation or settlement costs, delayed product approvals, currency volatility, working-capital changes, R&D execution risk, debt levels, raw material costs and competition in key therapies.
Glenmark has had dividend payouts in some years, but dividends are not guaranteed. Dividend amount, record date, ex-date and payment date should always be verified from the company, NSE and BSE announcements before relying on them.
Bonus and split information can change only through formal corporate action announcements. This page does not hard-code a bonus or split recommendation. Always verify the latest bonus, split, face value and record date details from official exchange filings.
The 52 week high and low show the highest and lowest traded prices over the last one year, based on the latest available market feed. Beginners use this range to understand price context, but it should not be treated as a buy or sell signal.
Start with revenue growth, operating profit margin, net profit, cash flow from operations, debt, working capital, debtor days and return ratios. Then compare the trend with peers and read management commentary for reasons behind one-time gains, litigation costs or exceptional items.
Glenmark is usually compared with listed pharmaceutical peers such as Sun Pharma, Cipla, Dr Reddy’s, Lupin, Torrent Pharma and Alkem. Comparisons should consider therapy mix, geography, regulatory track record, margins, R&D pipeline, balance sheet strength and valuation.
Useful monitorables include India formulation growth, North America and Europe revenue, EBITDA margin, product launch updates, USFDA status, litigation updates, debt reduction, cash generation, R&D spending, working-capital cycle and management guidance.
No. This page is educational and does not provide buy, sell or hold recommendations. Investors should use official filings, risk disclosures, financial statements and their own suitability analysis or consult a qualified adviser before making investment decisions.
